Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Sucampo Pharmaceuticals Inc

+ Add to Watchlist

R3A:GR

13.536 EUR 0.372 2.83%

As of 14:01:42 ET on 03/05/2015.

Snapshot for Sucampo Pharmaceuticals Inc (R3A)

Open: 13.196 Day's Range: 13.181 - 13.536 Volume: 0
Previous Close: 13.164 52wk Range: 4.297 - 14.541 1-Yr Rtn: +115.71%

Stock Chart for R3A

No chart data available.
  • R3A:GR 13.497
  • 1D
  • 1M
  • 1Y
13.164
Interactive R3A Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for R3A

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 21.9950
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) 0.6780
Est. PEG Ratio -
Market Cap (M EUR) 606.72
Shares Outstanding (M) 44.82
30 Day Average Volume 390
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for R3A

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for R3A

Sucampo Pharmaceuticals, Inc. researches and develops drugs based on protones, which are derived from functional fatty acids. The Company produces a prescription drug for the treatment of chronic idiopathic constipation.

Peter GreenleafChief Executive OfficerAndrew P SmithChief Financial Officer
Peter A KienerChief Scientific OfficerThomas J KnappExec VP/Chief Legal Ofcr/Secy
More Company Profile & Key Executives for R3A

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil